Clinical Trial Update: First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

First-in-human Phase I/II study of FHND-9041 in patients with EGFR-mutated advanced non-small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• FHND-9041

Snippet

Sponsor: Yongchang Zhang | Conditions: Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 1, Phase 2 | Status: COMPLETED